Moorfields board strengthened by new roles

Moorfields Eye Hospital is pleased to confirm several changes to its board, which will have a key impact as we drive forward our ambitious plans to deliver new, innovative services for patients and progress our plans for Oriel – a world-leading eye-care research, education and treatment facility in partnership with the Institute of Ophthalmology at University College London (UCL).

Executive directors
From 1 March, Johanna Moss, Moorfields’ director of strategy, will become a full voting member of the Moorfields board. Johanna will also see her role expanded to director of strategy and partnerships, in recognition of her leadership on Oriel and role in strengthening our relationships across the healthcare system and the sight loss community.

Also from 1 March, Jonathan Wilson, Moorfields’ chief financial officer, will also take on the role of deputy chief executive in recognition of his role in working closely alongside our partner organisations across the North Central London Integrated Care System.

Non-executive directors
Steve Williams, Moorfields’ senior independent director and vice chairman will be stepping down on 15 March following nine years as a non-executive director.

Adrian Morris, general counsel for Tesco and a member of the Tesco Group Executive Committee, will join Moorfields on 1 March as a non-executive director.

Commenting on the appointments, Tessa Green, chairman for Moorfields, said: “This is an exciting time for Moorfields as we look towards the future and progress our plans for Oriel, a modern and cutting edge eye-care facility in partnership with the Institute of Ophthalmology at UCL.

“I would like to thank Steve for his commitment and support to Moorfields, and for willingly giving so much of his time to support us on a range on activities and we wish him all the very best for the future.

“I would also like to extend a very warm welcome to Adrian. His commercial and legal insights will be invaluable to Moorfields as we seek to drive forward innovative services for patients and progress our plans for Oriel.” 

Was this information useful? Please rate the page.